Conditional Generative Adversarial Networks for Individualized Treatment Effect Estimation and Treatment Selection.

Area of Science:

• Oncology
• Artificial Intelligence
• Biostatistics

Background:

• Classical treatment response analysis assumes homogeneity, limiting precision oncology.
• Existing Artificial Intelligence (AI) methods like GANITE struggle with diverse treatment types and optimal selection.
• Precision oncology requires accurate estimation of individualized treatment effects for improved patient outcomes.

Purpose of the Study:

• To develop an AI approach for estimating individualized treatment effects across various treatment types (binary, categorical, continuous).
• To incorporate sparse techniques for biomarker selection to predict optimal treatments for individual patients.
• To evaluate the performance of the proposed method against existing state-of-the-art techniques.

Main Methods:

• Modified conditional generative adversarial networks (MCGANs) were developed to handle multi-type treatments.
• Sparse techniques were employed for biomarker selection to identify predictors of treatment efficacy.
• Simulations were conducted to compare MCGANs against seven other statistical and machine learning methods.

Main Results:

• MCGANs demonstrated superior performance in estimating individualized treatment effects compared to linear regression, KNN, random forests, logistic regression, and SVM.
• The application of MCGANs to acute myeloid leukemia (AML) patient data showed robust and accurate individualized treatment effect estimation.
• Key biomarkers including GSK3, BILIRUBIN, and SMAC were identified, with 30 biomarkers explaining 36.8% of treatment effect variation.

Conclusions:

• MCGANs offer a powerful and flexible AI framework for precision oncology, enabling accurate estimation of individualized treatment effects for diverse treatment modalities.
• The integration of sparse biomarker selection enhances the ability to personalize treatment strategies.
• This approach holds significant potential for improving treatment outcomes in complex diseases like AML.